Literature DB >> 6430215

The use of positron emission tomographic scanning in epilepsy.

J Engel.   

Abstract

Positron emission tomography (PET) with fluorine-18-labeled fluorodeoxyglucose (18FDG) has demonstrated the epileptogenic lesion in partial epilepsy to be hypometabolic interictally . This finding is useful for localizing the area of resection when surgical therapy is contemplated. 18FDG scans during partial seizures show increased metabolism in areas of ictal onset and spread and in other regions of decreased metabolism that could reflect postictal effects. In the generalized epilepsies, petit mal absences and generalized convulsions induced by electroconvulsive shock therapy (ECT) are associated with global hypermetabolism, while global hypometabolism is seen in the postictal period following ECT. More information about the factors that influence the interictal hypometabolic zone in partial epilepsy should improve the diagnostic value of this finding for presurgical localization and perhaps also for the evaluation of other therapeutic regimens. New techniques for more dynamic PET studies with improved resolution, combined with computerized electroencephalographic analysis, should allow more accurate interpretation of ictal, as well as interictal, phenomena. Application of PET technology to other paroxysmal disorders may provide a basis for new diagnostic classifications that have therapeutic and prognostic value and may allow clearer differentiation among epileptic phenomena, myoclonus, and movement disorders. More clinical and animal research is needed, however, before we can delineate fundamental mechanisms of human epilepsy from PET data. To this end, it is now possible to use combined multidisciplinary parallel approaches in patients and animals to define specific aspects of epileptic disorders clinically, to intensively investigate them with experimental models in the animal laboratory, and to verify the relevance of these experimental results by returning to clinical studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430215     DOI: 10.1002/ana.410150735

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

1.  Global and regional cerebral metabolic rate of 2-[18F]fluoro-2-deoxy-D-glucose in the presence of ofloxacin, a gamma-aminobutyric acid a receptor antagonist.

Authors:  E E Camargo; S Sostre; B Sadzot; I Shafique; Z Szabo; J M Links; R F Dannals; H N Wagner
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 2.  Epilepsy.

Authors:  J P Karis
Journal:  AJNR Am J Neuroradiol       Date:  2008-06       Impact factor: 3.825

3.  Single photon emission computed tomography with 99mTc HM-PAO in the study of focal epilepsy.

Authors:  E Grasso; L Ambrogio; A Cognazzo; P C Gerbino-Promis; P Zagnoni; G F Camuzzini; A Papaleo; F Acchiardi; G Perno
Journal:  Ital J Neurol Sci       Date:  1989-04

Review 4.  Magnetoencephalography in clinical epileptology and epilepsy research.

Authors:  C Baumgartner; L Deecke
Journal:  Brain Topogr       Date:  1990       Impact factor: 3.020

5.  A gut feeling about insular seizures.

Authors:  S Dionisio; A Koenig; J Murray; E Somerville
Journal:  BMJ Case Rep       Date:  2011-09-08

6.  Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy.

Authors:  Catherine Sharpe; Benjamin Sinclair; Patrick Kwan; Rodney J Hicks; Terence J O'Brien; Lucy Vivash
Journal:  Brain Imaging Behav       Date:  2021-10-20       Impact factor: 3.978

7.  CT, MR and SPECT imaging in temporal lobe epilepsy.

Authors:  R Duncan; J Patterson; D M Hadley; P Macpherson; M J Brodie; I Bone; A P McGeorge; D J Wyper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.